Stefania Chiappini
Overview
Explore the profile of Stefania Chiappini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
814
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chiappini S, Sampogna G, Ventriglio A, Menculini G, Ricci V, Pettorruso M, et al.
Expert Rev Neurother
. 2025 Feb;
:1-21.
PMID: 40013928
Introduction: The phenomenology of depression is characterized by a wide array of emotional, cognitive, and physical symptoms that significantly disrupt an individual's life. Societal changes, driven by technological advancements, economic...
2.
Mosca A, Chiappini S, Mancusi G, Miuli A, Marrangone C, Allegretti R, et al.
Curr Neuropharmacol
. 2025 Feb;
PMID: 39976040
Background: The widespread availability and accessibility of over-the-counter (OTC) medicines play a vital role in modern healthcare systems, enabling individuals to manage minor health concerns independently. However, certain OTC medications...
3.
Lupi M, Chiappini S, Mosca A, Miuli A, Di Muzio I, Marrangone C, et al.
Actas Esp Psiquiatr
. 2025 Jan;
53(1):165-180.
PMID: 39801408
Background: Alcohol Use Disorders (AUD), affective disorders, and personality disorders are among the most prevalent mental health conditions observed in individuals exhibiting suicidal behavior, encompassing both completed and attempted suicides....
4.
Chiappini S, Gramuglia P, Mosca A, Cavallotto C, Miuli A, Corkery J, et al.
Front Psychiatry
. 2024 Dec;
15:1508732.
PMID: 39624511
Background: Methylphenidate (MPH), a central nervous system stimulant primarily prescribed for attention-deficit/hyperactivity disorder (ADHD), has seen increasing rates of misuse and abuse, particularly in patients with dual diagnosis (co-occurring psychiatric...
5.
Montemitro C, Mosca A, Chiappini S, Miuli A, Schifano F, Montano M, et al.
Pharmaceuticals (Basel)
. 2024 Oct;
17(10).
PMID: 39459026
Background: illegal drugs significantly contribute to global health issues, with health complications often occurring not only in regular users with Substance Use Disorders (SUDs) but also in first-time and occasional...
6.
Chiappini S, Vaccaro G, Mosca A, Miuli A, Stigliano G, Stefanelli G, et al.
Neurosci Biobehav Rev
. 2024 May;
162():105691.
PMID: 38733894
The article presents a systematic literature review on the use and the psychiatric implications of over-the-counter drugs (OTC), prescription-only-medications (POM), and new psychoactive substances (NPS) within custodial settings. The searches...
7.
Chiappini S, Cavallotto C, Mosca A, Di Carlo F, Piro T, Giovannetti G, et al.
Pharmaceuticals (Basel)
. 2024 Apr;
17(4).
PMID: 38675495
Background: Dual disorders (DDs) involve the coexistence of a substance use disorder (SUD) with another mental illness, often from the psychotic and affective categories. They are quite common in clinical...
8.
Pepe M, Di Nicola M, Cocciolillo F, Chiappini S, Martinotti G, Calcagni M, et al.
Pharmaceuticals (Basel)
. 2024 Apr;
17(4).
PMID: 38675413
New Psychoactive Substances (NPS) are modifying the drug scenario worldwide and have become a public health concern because of their toxicological profiles and their harmful physical/psychological effects. 3-Methoxy-Phencyclidine (3-MeO-PCP), a...
9.
Cavallotto C, Chiappini S, Mosca A, dAndrea G, Di Carlo F, Piro T, et al.
J Clin Med
. 2024 Apr;
13(8).
PMID: 38673478
: Dual disorders (DD) entail the coexistence of a substance use disorder (SUD) and another mental health condition, often within psychotic and affective disorders. This study aims to evaluate lurasidone,...
10.
Ostuzzi G, Gastaldon C, Tettamanti M, Cartabia M, Monti I, Aguglia A, et al.
EClinicalMedicine
. 2024 Feb;
69:102491.
PMID: 38384338
Background: Major depressive disorder (MDD) is prevalent and disabling among older adults. Standing on its tolerability profile, vortioxetine might be a promising alternative to selective serotonin reuptake inhibitors (SSRIs) in...